Abstract:BACKGROUND:Schizophrenic patients treated with antipsychotic drugs (AP) have an increased frequency of glucose-lipid metabolic abnormalities and diabetes. Pioglitazone has been shown to be effective in the treatment of glucose and lipid abnormalities in diabetes and decreasing longer-term conversion of impaired glucose tolerance to frank diabetes. Some studies also suggest possible pro-cognitive and antidepressant effects of pioglitazone. We studied the effects of pioglitazone on potential metabolic, symptomatic and cognitive benefits in schizophrenic patients treated with AP.METHODS:54 schizophrenic patients with at least both a)impaired glucose and b) triglycerides≥120mg/dL and/or low HDL levels, participated in a double-blind placebo controlled study of 3month treatment with Pioglitazone (30-45mg/day) or matched placebo, at 5 sites (4 U.S., 1 China). Fasting glucose and lipid parameters, and psychopathology (PANSS scale) were assessed monthly, and patients had a glucose tolerance test and cognitive testing (RBANS and CPT) at baseline and at the end of study. Statistical analysis used mixed model repeated measures analysis, supplemented by completer and LOCF analysis.RESULTS:In the total sample there was an overall effect (P's<.05 to <.01) of pioglitazone on preventing deterioration in fasting glucose and improving HDL and PANSS depression scores; in the pioglitazone group comparison of baseline vs 3month values also showed significant (P<.05) decreases in fasting insulin, 2h glucose in GTT and insulin resistance (HOMA-IR). However there were marked differences between the responses of patients in the U.S. sites vs the China site. In the U.S. sample, patients treated with pioglitazone, when compared to placebo treated patents, had significantly lower fasting glucose (F=3.99, P=0.02), improved insulin sensitivity (lower H0MA-IR, F=6.24, P=.002), lower triglycerides (F=2.68, P=.06) and increased HDL (F=6.50, P=.001). By the end of the study 52% of the pioglitazone treated patients compared to 15% of the placebo patients had fasting glucose in the normal range (Fisher's exact test P=.02). Pioglitazone also significantly improved PANSS depression factor scores (F=2.82, P=0.05). It did not improve cognitive performance on the RBANS or CPT tasks. Pioglitazone did not increase weight or produce any other significant side-effects. In the small mainland China site sample, pioglitazone treatment, as compared to placebo, did not show greater improvement in metabolic parameters or psychopathology ratings.CONCLUSIONS:In the sample of patients from the U.S., pioglitazone was an efficacious and safe treatment for glucose and lipid metabolic abnormalities in schizophrenic patients treated with AP, and it may also have beneficial effects on depressive symptoms. It may be particularly useful in patients whose weight gain effects from antipsychotics have plateaued and where weight loss is not the primary goal. The risk vs. benefits of longer term treatment with pioglitazone has to be carefully evaluated for individual patients.

Pioglitazone as a potential modulator in autoimmune diseases: a review on its effects in systemic lupus erythematosus, psoriasis, inflammatory bowel disease, and multiple sclerosis

Mechanism of action and effect of immune-modulating agents in the treatment of psoriasis

Pioglitazone, Ppar Gamma Agonist, Attenuates Experimental Autoimmune Neuritis

Pioglitazone Ameliorates Nonalcoholic Steatohepatitis by Down-Regulating Hepatic Nuclear Factor-Kappa B and Cyclooxygenases-2 Expression in Rats.

Pioglitazone, PPARγ Agonist, Attenuates Experimental Autoimmune Neuritis

Neuroprotective and Anti-Inflammatory Effects of Pioglitazone on Parkinson's Disease: A Comprehensive Narrative Review of Clinical and Experimental Findings

Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis

Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases

Efficacy and Safety of Pioglitazone for Treatment of Plaque Psoriasis: a Systematic Review and Meta-Analysis of Randomized Controlled Trials

The roles of PPARγ and its agonists in autoimmune diseases: A comprehensive review

Pioglitazone Alleviates Β1-Adrenergic Receptor Antibody-Induced Atrial Fibrillation Susceptivity Via Mitigation of PPAR-γ-Mediated Metabolic Inflexibility.

Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications

Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus

Pioglitazone Ameliorates Atherosclerotic Lesions With The Modification Of The Balance Of Effector And Regulatory T Cells In Apolipoprotein E Deficient Mice

Protection of Pioglitazone for Diabetes Mellitus Beyond Its Hypoglycemic Effect

Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases

Pioglitazone Suppresses the Lipopolysaccharide-Induced Production of Inflammatory Factors in Mouse Macrophages by Inactivating Nf-Kappa B

Effects of Pioglitazone on Metabolic Abnormalities, Psychopathology, and Cognitive Function in Schizophrenic Patients Treated with Antipsychotic Medication: a Randomized Double-Blind Study.

Pioglitazone Reverses Markers of Islet Beta-Cell De-Differentiation in db/db Mice While Modulating Expression of Genes Controlling Inflammation and Browning in White Adipose Tissue from Insulin-Resistant Mice and Humans

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1

Pioglitazone Can Improve Liver Sex Hormone-Binding Globulin Levels and Lipid Metabolism in Polycystic Ovary Syndrome by Regulating Hepatocyte Nuclear Factor-4Α